184 related articles for article (PubMed ID: 8542250)
1. Interferon and multiple myeloma.
Lauta VM
Med Oncol; 1995 Mar; 12(1):63-9. PubMed ID: 8542250
[TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
3. [Interferon therapy in multiple myeloma].
Ludwig H; Scheithauer W; Kührer I; Kuzmits R; Gisslinger G; Linkesch W; Zielinski C; Fritz E
Onkologie; 1988 Aug; 11(4):192-6. PubMed ID: 3054670
[TBL] [Abstract][Full Text] [Related]
4. Interferons in the management of multiple myeloma.
Cooper MR
Semin Oncol; 1988 Oct; 15(5 Suppl 5):21-5. PubMed ID: 3057642
[No Abstract] [Full Text] [Related]
5. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
8. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
[TBL] [Abstract][Full Text] [Related]
10. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
[TBL] [Abstract][Full Text] [Related]
11. [Use of interferon alpha in multiple myeloma].
Harousseau JL; Klein B
Rev Med Interne; 1996; 17(6):488-95. PubMed ID: 8758538
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
15. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Björkholm M
Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
[No Abstract] [Full Text] [Related]
16. Is alpha-interferon treatment in multiple myeloma worthwhile?
Avvisati G; Petrucci MT
Stem Cells; 1995 Aug; 13 Suppl 2():106-13. PubMed ID: 8520497
[TBL] [Abstract][Full Text] [Related]
17. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
[TBL] [Abstract][Full Text] [Related]
18. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma].
Umeda M; Shirai T; Tsukahara T; Kaneko H; Yamauchi M; Arai N; Kosuge T; Kato M; Shikoshi K; Anno S
Rinsho Ketsueki; 1991 Jun; 32(6):669-74. PubMed ID: 1890744
[TBL] [Abstract][Full Text] [Related]
19. [Alpha-2a-interferon (Reaferon) in the treatment of patients with multiple myeloma].
Bessmel'tsev SS; Abdulkadyrov KM
Vopr Onkol; 1999; 45(4):393-7. PubMed ID: 10532098
[TBL] [Abstract][Full Text] [Related]
20. Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma.
Oken MM; Kyle RA
Semin Oncol; 1991 Oct; 18(5 Suppl 7):30-2. PubMed ID: 1948126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
